ACCC | FDA Approves Pembrolizumab + Axitinib for Advanced Renal Cell Carcinoma
FDA Approves Pembrolizumab + Axitinib for Advanced Renal Cell Carcinoma
On April 19, the FDA approved pembrolizumab (Keytruda, Merck & Co. Inc.) plus axitinib (Inlyta, Pfizer Inc.) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
In Person Conference & ConventionOctober 3, 2026 at 7:30 AM EDT8787 Keystone Crossing, Indianapolis, IN, USASheraton Indianapolis Hotel at Keystone Crossing, Indianapolis
In Person Conference & ConventionOctober 15, 2026 at 5:30 PM PDT255 N Virginia St, Reno, NV, USAWhitney Peak Hotel Reno, Tapestry Collection by Hilton, Reno
